Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

Nature Biotechnology

Volumn 33, Issue 10, 2015, Pages 1079-1086

  Dao, Tao ^a   Pankov, Dmitry ^a   Scott, Andrew ^a,b   Korontsvit, Tatyana ^a   Zakhaleva, Victoriya ^a   Xu, Yiyang ^c   Xiang, Jingyi ^c   Yan, Su ^c   De Morais Guerreiro, Manuel Direito ^a   Veomett, Nicholas ^a,b   Dubrovsky, Leonid ^a   Curcio, Michael ^a   Doubrovina, Ekaterina ^a   Ponomarev, Vladimir ^a   Liu, Cheng ^c   O'Reilly, Richard J ^a,b   Scheinberg, David A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c EUREKA THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; CELL MEMBRANES; CELLS; CYTOLOGY; EPITOPES; MOLECULES; MONOCLONAL ANTIBODIES; TUMORS;

CELL BASED THERAPIES; HUMAN LEUKOCYTE ANTIGEN; HUMAN T CELLS; MONOCLONAL ANTIBODIES (MAB); SMALL-MOLECULE DRUGS; T-CELL RECEPTORS; THERAPEUTIC EFFICACY; TUMOR ANTIGEN;

T-CELLS;

ANTINEOPLASTIC AGENT; BISPECIFIC T CELL ENGAGER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ESK1; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG; WT1 PROTEIN; CANCER VACCINE; ONCOPROTEIN; REPRESSOR PROTEIN; TUMOR ANTIGEN; WT1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; ANIMAL; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS; REPRESSOR PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84943591908     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3349     Document Type: Article

References (37)

1. Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P. and Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135-146 (2014).
2. Morris, E. et al. Generation of tumor-specific T-cell therapies. Blood Rev. 20, 61-69 (2006).
3. Dao, T. et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci. Transl. Med. 5, 176ra33 (2013).
4. Veomett, N. et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin. Cancer Res. 20, 4036-4046 (2014).
5. Dubrovsky, L. et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 123, 3296-3304 (2014).
6. Curran, K.J., Pegram, H.J. and Brentjens, R.J. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J. Gene Med. 14, 405-415 (2012).
7. Sadelain, M., Brentjens, R. and Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398 (2013).
8. Frankel, S.R. and Baeuerle, P.A. Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 17, 385-392 (2013).
9. Nagorsen, D. and Baeuerle, P.A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp. Cell Res. 317, 1255-1260 (2011).
10. Brischwein, K. et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30, 798-807 (2007).
11. Brentjens, R.J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
12. Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98-104 (2005).
13. Mittendorf, E.A., Holmes, J.P., Ponniah, S. and Peoples, G.E. The E75 HER2/neu peptide vaccine. Cancer Immunol. Immunother. 57, 1511-1521 (2008).
14. Doubrovina, E. et al. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood 120, 1633-1646 (2012).
15. Pedersen, A.E. et al. Wild type p53-specific antibody and T-cell responses in cancer patients. J. Immunother. 34, 629-640 (2011).
16. Kessler, J.H. et al. Efficient identification of novel HLA-A(∗)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193, 73-88 (2001).
17. Quintarelli, C. et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 117, 3353-3362 (2011).
18. Dao, T. et al. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One 4, e6730 (2009).
19. Peralbo, E., Alonso, C. and Solana, R. Invariant NKT and NK-like lymphocytes: Two different T cell subtypes that are differentially affected by aging. Exp. Gerontol. 42, 703-708 (2007).
20. Oka, Y. et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Scientific World Journal 7, 649-665 (2007).
21. Cheever, M.A. et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323-5337 (2009).
22. Chapuis, A.G. et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 5, 174ra27 (2013).
23. Sergeeva, A. et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117, 4262-4272 (2011).
24. Corbière, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253-1262 (2011).
25. Hunder, N.N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008).
26. Abès, R., Gelize, E., Fridman, W.H. and Teillaud, J.L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116, 926-934 (2010).
27. Selenko, N. et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 15, 1619-1626 (2001).
28. Hilchey, S.P. et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 113, 3809-3812 (2009).
29. Ott, P.A., Hodi, F.S. and Robert, C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 19, 5300-5309 (2013).
30. Tumeh, P.C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
31. Gubin, M.M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
32. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
33. Inoue, K. et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405-1412 (1997).
34. Oka, Y. et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Scientific World Journal 7, 649-665 (2007).
35. Brischwein, K. et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43, 1129-1143 (2006).
36. Fan, L. et al. Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells. Biotechnol. Bioeng. 109, 1007-1015 (2012).
37. Doubrovina, E. et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119, 2644-2656 (2012).